| Date | Title | Description |
| 10.01.2024 | Development Bank of Japan invests in 4BIO Capital’s Ventures... | 4BIO Ventures III targeting $200-300 million to unlock the treatments of the future by investing in ... |
| 13.11.2023 | 4BIO Capital jointly leads $25 million Series A financing of... | - ViaNautis’s proprietary drug delivery platform polyNaut® is designed to deliver genetic therapeuti... |
| 13.11.2023 | 4BIO Capital jointly leads $25 million Series A financing of... | - |
| 12.11.2023 | Araris Biotech AG Announces Research Collaboration with Taih... | AU ZH, SWITZERLAND, November 8, 2023 – Araris Biotech AG (“Araris”), a Swiss oncology biotech compan... |
| 09.11.2023 | Araris Biotech AG Announces Research Collaboration with Taih... | AU ZH, SWITZERLAND, November 8, 2023 – Araris Biotech AG (“Araris”), a Swiss oncology biotech compan... |
| 09.11.2023 | Araris Biotech AG Announces Research Collaboration with Taih... | - |
| 30.10.2023 | SparingVision named a ‘Fierce 15’ Company by Fierce Biotech... | SparingVision, a clinical-stage genomic medicine company developing vision-saving treatments for ocu... |
| 29.08.2023 | SparingVision named a ‘Fierce 15’ Company by Fierce Biotech... | - |
| 04.07.2023 | Cell and gene therapy manufacturing: the next generation of ... | 4BIO Capital portfolio company Ascend Gene and Cell Therapies has featured in a BioPharma Dive artic... |
| 26.06.2023 | Cell and gene therapy manufacturing: the next generation of ... | 4BIO Capital portfolio company Ascend Gene and Cell Therapies has featured in a BioPharma Dive artic... |
| 18.05.2023 | 4BIO Capital Participates in $130M Funding of New Gene and C... | Expert transatlantic teams merge to establish Ascend as new facilitator for gene and cell therapy co... |
| 18.05.2023 | 4BIO Capital Portfolio Company Ray Therapeutics Closes Overs... | - Ray Therapeutics Closes Oversubscribed $100M Series A Financing
- Series A follows initial seed i... |
| 16.05.2023 | 4BIO Capital Portfolio Company Ray Therapeutics Closes Overs... | - |
| 16.05.2023 | 4BIO Capital Portfolio Company Ray Therapeutics Closes Overs... | - Ray Therapeutics Closes Oversubscribed $100M Series A Financing
- Series A follows initial seed i... |
| 09.05.2023 | 4BIO Capital Participates in $130M Funding of New Gene and C... | Expert transatlantic teams merge to establish Ascend as new facilitator for gene and cell therapy co... |
| 17.12.2022 | 4BIO Capital Portfolio Company Entact Bio Launches with $81 ... | Company’s proprietary end-to-end Encompass™ platform designs enhancement-targeting chimeric (ENTAC™)... |
| 07.12.2022 | Entact Bio Launch with $81M Series A to Develop Precision Me... | Launch fueled by syndicate of blue-chip investors co-led by Qiming Venture Partners USA and venBio P... |
| 06.12.2022 | 4BIO Capital Portfolio Company Entact Bio Launches with $81 ... | Company’s proprietary end-to-end Encompass™ platform designs enhancement-targeting chimeric (ENTAC™)... |
| 06.12.2022 | 4BIO Capital Portfolio Company Entact Bio Launches with $81 ... | - |
| 02.12.2022 | SparingVision’s lead asset SPVN06 clears IND application in ... | SparingVision set to advance into the clinic with breakthrough gene-independent approach targeting r... |
| 01.12.2022 | SparingVision’s lead asset SPVN06 clears IND application in ... | - |
| 01.12.2022 | SparingVision’s lead asset SPVN06 clears IND application in ... | SparingVision set to advance into the clinic with breakthrough gene-independent approach targeting r... |
| 22.11.2022 | 4BIO Capital Portfolio Company Redpin Therapeutics to be Acq... | London & New York – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm ... |
| 16.11.2022 | 4BIO Capital Portfolio Company Redpin Therapeutics to be Acq... | - |
| 16.11.2022 | 4BIO Capital Portfolio Company Redpin Therapeutics to be Acq... | London & New York – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm ... |
| 04.10.2022 | Araris Biotech Closes $24 Million Financing Round | AU ZH, SWITZERLAND / October 4, 2022 / Araris Biotech AG (“Araris” or “the Company”), a company pion... |
| 04.10.2022 | Araris Biotech Closes $24 Million Financing Round | AU ZH, SWITZERLAND / October 4, 2022 / Araris Biotech AG (“Araris” or “the Company”), a company pion... |
| 04.10.2022 | Araris Biotech Closes $24 Million Financing Round | - |
| 21.09.2022 | 4BIO Capital Portfolio Company Carisma Therapeutics and Sese... | 21 September 2022
LONDON – 4BIO Capital, an international venture capital firm investing in advance... |
| 21.09.2022 | 4BIO Capital Portfolio Company Carisma Therapeutics and Sese... | - |
| 21.09.2022 | 4BIO Capital Portfolio Company Carisma Therapeutics and Sese... | 21 September 2022
LONDON – 4BIO Capital, an international venture capital firm investing in advance... |
| 17.09.2022 | SparingVision Raises €75 Million Series B | LONDON– 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm unlocking the tr... |
| 14.09.2022 | SparingVision Raises €75 Million Series B | - |
| 08.06.2022 | 4BIO Capital Portfolio Company Code Biotherapeutics Closes a... | London & Greater Philadelphia – 4BIO Capital (“4BIO” or “the Group”), an international venture c... |
| 08.06.2022 | 4BIO Capital Portfolio Company Code Biotherapeutics Closes a... | - |
| 06.06.2022 | 4BIO Capital co-leads $30 million (¥3.86 Billion) oversubscr... | - |
| 06.06.2022 | 4BIO Capital co-leads $30 million (¥3.86 Billion) oversubscr... | - Financing reflects the potential of mitochondrial therapy to restore cellular bioenergetics in dys... |
| 12.05.2022 | Ray Therapeutics Receives $4M in Funding from the California... | 27 April 2022
LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture ... |
| 27.04.2022 | Ray Therapeutics Receives $4M in Funding from the California... | 27 April 2022
LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture ... |
| 27.04.2022 | Ray Therapeutics Receives $4M in Funding from the California... | - |
| 02.03.2022 | 4BIO Capital announces promotion of Owen Smith to Partner an... | LONDON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely ... |
| 02.03.2022 | 4BIO Capital announces promotion of Owen Smith to Partner an... | - |
| 01.03.2022 | Code Biotherapeutics Announces Collaboration with Takeda | Code Biotherapeutics, Inc. (Code Bio), a biotechnology company pioneering targeted non-viral deliver... |
| 22.02.2022 | Code Biotherapeutics Announces Collaboration with Takeda | - |
| 10.01.2022 | 4BIO Capital Portfolio Company Carisma to Collaborate with M... | LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm fo... |
| 10.01.2022 | 4BIO Capital Portfolio Company Carisma to Collaborate with M... | - |
| 04.01.2022 | 4BIO Capital Leads $6 Million Seed Financing in Ray Therapeu... | - |
| 04.01.2022 | 4BIO Capital Leads $6 Million Seed Financing in Ray Therapeu... | LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm fo... |
| 13.12.2021 | 4BIO Capital to Use Insig AI’s Technology to Accelerate the ... | - |
| 13.12.2021 | 4BIO Capital to Use Insig AI’s Technology to Accelerate the ... | LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm fo... |
| 02.12.2021 | 4BIO Capital Announces Strategic Partnership with Harbor Cap... | London, 2 December 2021 – 4BIO Capital (“4BIO” or “the Group”), an international asset management fi... |
| 02.12.2021 | 4BIO Capital Announces Strategic Partnership with Harbor Cap... | - |
| 13.10.2021 | SparingVision announces strategic collaboration with Intelli... | London, 13 October 2020 – 4BIO Capital (“4BIO” or “the Group”), an international venture capital fir... |
| 13.10.2021 | SparingVision announces strategic collaboration with Intelli... | - |
| 20.04.2021 | 4BIO Capital Co-leads $10 Million Seed Financing in Code Bio... | LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm fo... |
| 20.04.2021 | SparingVision Expands Novel Ocular Disease Pipeline with Acq... | Paris, April 20, 2021 – SparingVision (the “Company”), a genomic medicines company developing vision... |
| 01.03.2021 | 4BIO Joins Investor Syndicate in CARISMA Therapeutics’ Secon... | LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm fo... |
| 01.03.2021 | 4BIO Joins Investor Syndicate in CARISMA Therapeutics’ Secon... | - |
| 25.01.2021 | 4BIO Capital’s review of AAV gene therapy clinical trials pu... | - |
| 25.01.2021 | 4BIO Capital’s review of AAV gene therapy clinical trials pu... | LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm fo... |
| 22.12.2020 | Orchard Therapeutics Receives EC Approval for Treatment of E... | - |
| 22.12.2020 | Orchard Therapeutics Receives EC Approval for Treatment of E... | LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm fo... |
| 18.12.2020 | Appointment of Professor Akiko Iwasaki to Scientific Advisor... | LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm fo... |
| 18.12.2020 | Appointment of Professor Akiko Iwasaki to Scientific Advisor... | - |
| 20.11.2020 | ADC Therapeutics Announces FDA’s Acceptance of its Biologics... | - |
| 20.11.2020 | ADC Therapeutics Announces FDA’s Acceptance of its Biologics... | LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm fo... |
| 22.10.2020 | 4BIO Capital invests in Araris Biotech AG’s CHF 15.2 million... | - |
| 22.10.2020 | 4BIO Capital invests in Araris Biotech AG’s CHF 15.2 million... | · Dmitry Kuzmin, Managing Partner, to join as Board member
· Proceeds to support advancement of lea... |
| 21.10.2020 | 4BIO Capital leads SparingVision’s €44.5 million financing r... | LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm fo... |
| 13.07.2020 | 4BIO Capital announces appointment of Professor Kenya Honda ... | LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm fo... |
| 01.07.2020 | 4BIO Capital appoints Brian P. McVeigh as Venture Partner | - |
| 01.07.2020 | 4BIO Capital appoints Brian P. McVeigh as Venture Partner | LONDON & PHILADELPHIA – 4BIO Capital (“4BIO” or “the Group”), an international venture capital f... |
| 08.06.2020 | 4BIO Capital announces strategic investment from Japanese ph... | - |
| 08.06.2020 | 4BIO Capital announces strategic investment from Japanese ph... | LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm fo... |
| 20.05.2020 | 4BIO Capital portfolio company ADC Therapeutics SA closes an... | - |
| 20.05.2020 | 4BIO Capital portfolio company ADC Therapeutics SA closes an... | LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm fo... |
| 19.05.2020 | 4BIO Capital publishes review of AAV gene therapies in Cell ... | LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm fo... |
| 25.03.2020 | 4BIO Capital leads Redpin Therapeutics’ $15.5 million Series... | LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm fo... |
| 25.03.2020 | 4BIO Capital leads Redpin Therapeutics’ $15.5 million Series... | - |
| 01.11.2019 | Data suggest gene, cell therapy trial initiations in Europe ... | 4BIO's Dmitry Kuzmin and Owen Smith enjoyed speaking to Natalie Grover at Endpoints on the state of ... |
| 01.11.2019 | Data suggest gene, cell therapy trial initiations in Europe ... | - |
| 30.09.2019 | 4BIO Capital appoints Philippe Fauchet, OBE, as Venture Part... | LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm fo... |
| 09.09.2019 | 4BIO Capital raises $50 million in first close of new advanc... | - |
| 09.09.2019 | 4BIO Capital raises $50 million in first close of new advanc... | 4BIO Ventures II fund solely focused on advanced therapies targeting $150 million final close
LON... |
| 25.02.2019 | Spark Therapeutics enters into definitive merger agreement w... | Roche to acquire Spark Therapeutics for $114.50 per share representing a total equity value of $4.8 ... |
| 22.02.2019 | 4BIO portfolio company Orchard Therapeutics announces ADA-SC... | - |
| 22.02.2019 | 4BIO portfolio company Orchard Therapeutics announces ADA-SC... | Orchard Therapeutics plc (Nasdaq:ORTX) presents Two-Year Follow-Up Data versus historical control fr... |
| 10.11.2018 | EGLSF I wins two EuroHedge Emerging Fund Management Awards | 4BIO Capital is proud to announce that EG Life Sciences Fund I Ltd (EGLSF 1, or the “Fund”), has won... |
| 10.11.2018 | EGLSF I wins two EuroHedge Emerging Fund Management Awards | - |
| 01.11.2018 | 4BIO portfolio company Orchard Therapeutics goes public | Orchard Therapeutics plc (Nasdaq:ORTX), a biopharmaceutical company dedicated to transforming the li... |
| 01.11.2018 | 4BIO portfolio company Orchard Therapeutics goes public | - |
| 13.08.2018 | 4BIO portfolio company Orchard Therapeutics Announces $150 M... | Orchard Therapeutics, a leading commercial-stage company dedicated to transforming the lives of pati... |
| 10.05.2018 | Fellowship of the Royal Society elections | - |
| 10.05.2018 | Fellowship of the Royal Society elections | 4BIO Capital extends warm congratulations to Professor Dimitri Kullman, member of our Scientific Adv... |
| 13.04.2018 | GSK Hands Off Rare Disease Gene Therapy Portfolio to Orchard... | GlaxoSmithKline (GSK) said today it will hand off its rare disease gene therapy portfolio — includin... |
| 24.03.2018 | TiGenix and Takeda announce Alofisel® (darvadstrocel) receiv... | TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) and Takeda Pharmaceutical Company Limited... |
| 05.01.2018 | Takeda announces its intention to acquire TiGenix | - |
| 05.01.2018 | Takeda announces its intention to acquire TiGenix | TiGenix NV ("TiGenix") (Euronext Brussels and NASDAQ: "TIG"), an advanced biopha... |
| 03.01.2018 | Spark Therapeutics Announces Pricing and First-of-their-kind... | - |
| 03.01.2018 | Spark Therapeutics Announces Pricing and First-of-their-kind... |
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challengi... |
